The chronic venous occlusions treatment market includes
Manufacturers viz.
Stryker Corporation
Bristol Myers Squibb
Boston Scientific Corporation
Sanofi
Bayer AG
Medtronic plc
Pfizer Inc.
Tactile Medical
Julius Zorn GmbH
Smith & Nephew PLC
Viatris Inc.
Merz Pharma
Candela
Sciton, Inc
Fotona
3M Company
ConvaTec Inc.
Medi GmbH & Co. KG
Sigvaris AG
Leucadia Pharmaceuticals (Hikma)
Lumenis Ltd.
Venclose, Inc. (Becton Dickinson and Company)
Authors:
Mariam Faizullabhoy
Frequently Asked Questions (FAQ) :
Global market for chronic venous occlusions treatment was valued at over USD 5.5 billion in 2021 and is estimated to grow significantly at a 5.5% CAGR through 2030 primarily driven by the rising awareness about available treatment options for chronic venous occlusion.
Drugs segment is projected to exceed USD 4.6 billion in revenue by 2030. The increasing awareness about the benefits of drugs for the treatment of chronic venous occlusion is anticipated to boost product demand.
Asia Pacific chronic venous occlusions treatment market is anticipated to expand at a 6.5% CAGR between 2022 and 2030 owing to the growing prevalence of varicose veins among adults and early diagnosis of chronic venous illnesses in the region.
The competitive landscape of the market includes Boston Scientific Corporation, Essity AB, Stryker Corporation, Bristol Myers Squibb, Medtronic plc, Pfizer Inc., ISOMed, Cardinal Health, SerenaGroup, Tactile Medical, Julius Zorn GmbH, Smith & Nephew PLC, Viatris Inc., Merz Pharma, Fotona, 3M Company, ConvaTec Inc., and other firms.